Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 843-852

  Webb, Randy L ^a   Navarrete, Aida E ^a   Davis, Scott ^a   De Gasparo, Marc ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II type 1 receptor antagonist; Benazeprilat; Spontaneously hypertensive rats; Telemetry; Valsartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; BENAZEPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; DRUG ANTAGONISM; HEART RATE; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY;

EID: 0031808255     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00016     Document Type: Article

References (42)

1. Chan PS, Ronsberg MA, Cervoni P. Acute antihypertensive synergism of angiotensin converting enzyme inhibitors and diuretics. Fed Proc 1984; 43:1346-1350.
2. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150:1175-1183.
3. van den Meiracker AH, Man in't Veld AJ, Admiraal PJJ, Ritsema van Eck HJ, Boomsma F, Derkx FHM, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992; 10:803-812.
4. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin H during ACE inhibition. J Cardiovasc Pharmacol 1990; 15:276-282.
5. Juillerat L, Nussberger J, Ménard J, Mooser V, Christen Y, Waeber B, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:564-572.
6. Fossa AA, DePasquale MJ, Ringer LJ, Winslow RL. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist. Drug Dev Res 1994; 33:422-428.
7. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92:825-834.
8. 1-receptor subtype. Br J Pharmacol 1993; 110:761-771.
9. Bazil MK, Krulan C, Webb RL. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22:897-905.
10. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7 (suppl I):I1-I7.
11. Kotz S, Johnson NL. Encyclopedia of statistical sciences, Vol. 9, New York: John Wiley and Sons; 1988.
12. Snedecor GW, Cochran WG. Statistical methods. 8th Edition, Iowa State University Press; 1989, pp. 89-169.
13. Glantz SA. Primer of biostatistics. 3rd Edition, New York: McGraw Hill, Inc.; 1992, pp. 95-96.
14. Wood JM, Schnell CR, Levens NR. Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats. Hypertension 1993; 21:1056-1061.
15. Bunkenburg B, Schnell C, Baum HP, Cumin F, Wood JM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hypertension 1991; 18:278-288.
16. Trapani AJ, Smits JFM, Sun XJ, Webb RL, Yau ET. CGS 24128: a long-acting inhibitor of neutral endopeptidase 2.4.24.11. Cardiovasc Drug Rev 1994; 12:271-285.
17. 7 Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13: 230-250.
18. Waldmeier F, Schmid K. Disposition of [14C]-benazepril hydrochloride in rat, dog and baboon. ArzneimitteHorschung 1989; 39:62-67.
19. Muirhead EE, Prewitt RL, Brooks B, Brosius WL Antihypertensive action of the orally active converting enzyme inhibitor (SQ 14225) in spontaneously hypertensive rats. Circ Res 1978; 43 (suppl I):I53-I58.
20. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. In vivo pharmacology of DuP 753. Am J Hypertens 1991; 4 (suppl): 288S-298S.
21. Reid IA. Actions of angiotensin II on the brain: mechanisms and physiologic role. Am J Physiol 1984; 246:F533-F543.
22. 1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988; 338:185-190.
23. Scroop GC, Lowe RD. Efferent pathways of cardiovascular response to vertebral artery infusions of angiotensin in the dog. Clin Sci 1969; 37:605-619.
24. Potter EK. Angiotensin inhibits action of vagus nerve at the heart. Br J Pharmacol 1982; 75:9-11.
25. Waldmeier F, Schmid K. Disposition of [14C]-benazepril hydrochlorothiazide in rat, dog, and baboon. ArzneimitteHorschung 1989; 39:62-67.
26. Zimmerman MB, Barclay BW, Lehmann M, Norman JA. Effects of chronic administration of angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin Exp Hypertens [A] 1987; 9:473-476.
27. De Champlain J, Genest J, Veyrat R, Boucher R. Factors controlling renin release in man. Arch Intern Med 1966; 117:355-363.
28. Hodsmans GP, Zabludowski JR, Zoccali C, Fraser R, Morton JJ, Murray GD, et al. Enalapril (MK 421) and its lysine analogue (MK 521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. J Clin Pharmacol 1984; 17:233-241.
29. Mento PF, Holt WF, Murphy WR, Wilkes BM. Combined renin and converting enzyme inhibition in rats. Hypertension 1989; 13: 741-748.
30. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993; 11:1155-1159.
31. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol 1996; (suppl 3): S125-S131.
32. Maxwell SRJ. ACE inhibition in the 1990s. Br J CHn Pharmacol 1993; 47:127-135.
33. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987; 9 (suppl III):III42-III48.
34. Fossa AA, Weinberg LJ, Barber RL, Rauch AL, Nocerini MR, Murphy WR, ef al. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol 1992; 20:75-82.
35. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640.
36. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens B. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
37. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30:535-541.
38. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377:748-750.
39. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20:74-79.
40. Bao G, Gohlke P, Unger T. Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 1992; 20 (suppl 9):S96-S99.
41. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 1993; 14:883-891.
42. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RAS. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 1997; 30:542-548.